Back to discover

Protein / target

T-cell surface glycoprotein CD3 epsilon chain

Encoded byCD3EP07766Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
12
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Signaling receptor complex adaptor

Strongest disease association

Immunodeficiency 18

Via encoding gene CD3E · Genetic evidence · score 0.92

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.

View complete UniProt function annotation

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response (PubMed:15294938, PubMed:15546002, PubMed:2470098, PubMed:40592325, PubMed:8490660). When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z (PubMed:2470098, PubMed:40592325). All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain (PubMed:2470098, PubMed:40592325). Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098, PubMed:40592325). CD3E ITAM phosphorylation creates docking sites for the protein kinase ZAP70 leading to ZAP70 phosphorylation and its conversion into a catalytically active enzyme (By similarity). In addition of this role of signal transduction in T-cell activation, CD3E plays an essential role in correct T-cell development (By similarity). Also participates in internalization and cell surface down-regulation of TCR-CD3 complexes via endocytosis sequences present in CD3E cytosolic region (PubMed:10384095, PubMed:26507128). In addition to its role as a TCR coreceptor, it serves as a receptor for ITPRIPL1 (PubMed:38614099). Ligand recognition inhibits T-cell activation by promoting interaction with NCK1, which prevents CD3E-ZAP70 interaction and blocks the ERK-NFkB signaling cascade and calcium influx (PubMed:12110186, PubMed:38614099)

Subcellular location

Cell membrane
Domains and Gene Ontology detail (36)

Domains & features

Ig-likeITAM

Gene Ontology

  • Calpha-beta T cell receptor complex
  • Ccell body
  • Ccell-cell junction
  • Cdendritic spine
  • Cexternal side of plasma membrane
  • Cimmunological synapse
  • Cplasma membrane
  • CT cell receptor complex
  • Fidentical protein binding
  • Fprotein kinase binding
  • Fprotein-macromolecule adaptor activity
  • FSH3 domain binding

207 aa · 23 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Receptor tyrosine kinase signallingGOImmune signallingUniProt · GOCell adhesionGOTranscriptional regulationGO
View supporting evidence

Receptor tyrosine kinase signalling

  • ·cell surface receptor protein tyrosine kinase signaling pathway

Immune signalling

  • ·Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential…
  • ·alpha-beta T cell receptor complex
  • ·T cell receptor complex
  • ·T cell receptor binding

Cell adhesion

  • ·cell-cell junction
  • ·positive regulation of cell-cell adhesion mediated by integrin

Transcriptional regulation

  • ·negative regulation of gene expression
  • ·positive regulation of gene expression
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CD3GCD247CD3DZAP70SYKCD8ACD4CD8BLCKTRAT1CD3E

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

7 medicines · 6 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Multiple Myeloma3 medicines
Lymphoma, Large B-Cell, Diffuse2 medicines
Lymphoma, Follicular1 medicine
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma1 medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma1 medicine

12 medicines meet Open Targets' target-level approved-medicine definition; the 7 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

8

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

ertumaxomab
Narrow target profilePhase 2Cross-linking agent

T-cell surface glycoprotein CD3 epsilon chain cross-linking agent

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

blinatumomab
ApprovedCross-linking agent

T cell surface glycoprotein CD3 cross-linking agent

Indicated for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

glofitamab
ApprovedBinding agent

T cell surface glycoprotein CD3 binding agent

Indicated for Lymphoma, Large B-Cell, Diffuse, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

catumaxomab
ApprovedCross-linking agent

T cell surface glycoprotein CD3 cross-linking agent

Indicated for Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

elranatamab
ApprovedBinding agent

T cell surface glycoprotein CD3 binding agent

Indicated for Multiple Myeloma, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

epcoritamab
ApprovedBinding agent

T cell surface glycoprotein CD3 binding agent

Indicated for Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

View all 8 targeting drugs
talquetamab
ApprovedBinding agent

T cell surface glycoprotein CD3 binding agent

Indicated for Multiple Myeloma, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 3 recorded protein targets — narrow recorded profile

teclistamab
ApprovedBinding agent

T cell surface glycoprotein CD3 binding agent

Indicated for Multiple Myeloma, Neoplasms

Acts on a complex — shared with CD3D, CD3G · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CD3E

Gene-level evidence surfaced through the gene CD3Ethat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Immunodeficiency 18
0.94Well supported

Genetic evidence dominant · Open Targets 0.74

Neoplasms
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Multiple Myeloma
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Precursor Cell Lymphoblastic Leukemia-Lymphoma
0.72Moderately supported

Clinical evidence dominant · Open Targets 0.58

Lymphoma, Follicular
0.72Moderately supported

Clinical evidence dominant · Open Targets 0.58

View evidence synthesis (5)
Immunodeficiency 18Well supported
0.94
agreement 0.811.00
Genetic80%Animal model20%Genetic literaturedup

Open Targets aggregate 0.74 · 2 independent evidence families · 1 not counted as duplicate

NeoplasmsModerately supported
0.74
agreement 0.590.90
Clinical85%Literature16%

Open Targets aggregate 0.60 · 2 independent evidence families

Multiple MyelomaModerately supported
0.74
agreement 0.580.89
Clinical99%Literature1%

Open Targets aggregate 0.60 · 2 independent evidence families

Precursor Cell Lymphoblastic Leukemia-LymphomaModerately supported
0.72
agreement 0.570.88
Clinical86%Literature14%

Open Targets aggregate 0.58 · 2 independent evidence families

Lymphoma, FollicularModerately supported
0.72
agreement 0.560.87
Clinical100%Literature0%

Open Targets aggregate 0.58 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Immunodeficiency 180.74
Neoplasms0.60
Multiple Myeloma0.60
Lymphoma, Follicular0.58
Lymphoma, Large B-Cell, Diffuse0.58
Precursor Cell Lymphoblastic Leukemia-Lymphoma0.58
Diabetes Mellitus, Type 10.56
Small Cell Lung Carcinoma0.56
B-cell acute lymphoblastic leukemia0.47

Drug development

22 compounds recorded · 12 approved · 10 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 8 drugs that target this protein in Forefront's canonical graph (7 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
OTELIXIZUMABPhase 3
ERTUMAXOMABPhase 2
BLINATUMOMABApproval
TEPLIZUMABApproval
TARLATAMABApproval
FLOTETUZUMABPhase 2
TALQUETAMABApproval
EPCORITAMABApproval
FORALUMABPhase 2
IMC-GP100Early Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and med-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Approved Drug and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (10)
SM · Structure with LigandSM · Med-Quality PocketAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Database UbiquitinationPR · Half-life DataOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

NOT_YET_RECRUITING · via blinatumomab · NCT07297914

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 6 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-07-30

    64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

    Status changed to Active, not recruiting · ClinicalTrials.gov · via talquetamab

  2. Trial status changed2026-07-20

    A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

    Status changed to Active, not recruiting · ClinicalTrials.gov · via teclistamab

  3. Trial status changed2026-07-17

    A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

    Status changed to Active, not recruiting · ClinicalTrials.gov · via glofitamab

  4. Label change2026-06-22

    Label change: GLOFITAMAB (BLA761309)

    fda · regulatory · fda · via glofitamab

  5. Label change2026-06-17

    Label change: EPCORITAMAB-BYSP (BLA761324)

    fda · regulatory · fda · via epcoritamab

  6. Label change2026-05-28

    Label change: GLOFITAMAB (BLA761309)

    fda · regulatory · fda · via glofitamab

  7. Indication expanded2026-03-27

    Indication expansion: EPCORITAMAB-BYSP (BLA761324)

    fda · regulatory · fda · via epcoritamab

  8. Indication expanded2025-11-18

    Indication expansion: EPCORITAMAB-BYSP (BLA761324)

    fda · regulatory · fda · via epcoritamab

  9. Label change2025-10-27

    Label change: GLOFITAMAB (BLA761309)

    fda · regulatory · fda · via glofitamab

  10. New publication2020-05-13
    The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.

    Cancer · 2020 · 180 citations · Europe PMC · via blinatumomab

  11. New publication2018-01-22
    Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

    Blood · 2018 · 635 citations · Europe PMC · via blinatumomab

  12. New publication2009-04-03
    The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

    The oncologist · 2009 · 825 citations · Europe PMC · via ertumaxomab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.